Seroatlas · Human Serome Atlas

CELSR2

Cadherin EGF LAG seven-pass G-type receptor 2

Also known as: ADGRC2, CDHF10, CELR2_HUMAN, EGFL2, Flamingo1, KIAA0279, MEGF3

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9HCU4
Gene: CELSR2
Ensembl: ENSG00000143126
Chromosome: 1
Canonical length: 2923 aa
Protein class: G-protein coupled receptors, Predicted membrane proteins
Subcellular location: Vesicles,Cytosol

OverviewNCBI Gene

The protein encoded by this gene is a member of the flamingo subfamily, part of the cadherin superfamily. The flamingo subfamily consists of nonclassic-type cadherins; a subpopulation that does not interact with catenins. The flamingo cadherins are located at the plasma membrane and have nine cadherin domains, seven epidermal growth factor-like repeats and two laminin A G-type repeats in their ectodomain. They also have seven transmembrane domains, a characteristic unique to this subfamily. It is postulated that these proteins are receptors involved in contact-mediated communication, with cadherin domains acting as homophilic binding regions and the EGF-like domains involved in cell adhesion and receptor-ligand interactions. The specific function of this particular member has not been determined. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

2923 residues, UniProt reviewed canonical sequence.

>Q9HCU4|CELSR2
     1  MRSPATGVPL PTPPPPLLLL LLLLLPPPLL GDQVGPCRSL GSRGRGSSGA CAPMGWLCPS
    61  SASNLWLYTS RCRDAGTELT GHLVPHHDGL RVWCPESEAH IPLPPAPEGC PWSCRLLGIG
   121  GHLSPQGKLT LPEEHPCLKA PRLRCQSCKL AQAPGLRAGE RSPEESLGGR RKRNVNTAPQ
   181  FQPPSYQATV PENQPAGTPV ASLRAIDPDE GEAGRLEYTM DALFDSRSNQ FFSLDPVTGA
   241  VTTAEELDRE TKSTHVFRVT AQDHGMPRRS ALATLTILVT DTNDHDPVFE QQEYKESLRE
   301  NLEVGYEVLT VRATDGDAPP NANILYRLLE GSGGSPSEVF EIDPRSGVIR TRGPVDREEV
   361  ESYQLTVEAS DQGRDPGPRS TTAAVFLSVE DDNDNAPQFS EKRYVVQVRE DVTPGAPVLR
   421  VTASDRDKGS NAVVHYSIMS GNARGQFYLD AQTGALDVVS PLDYETTKEY TLRVRAQDGG
   481  RPPLSNVSGL VTVQVLDIND NAPIFVSTPF QATVLESVPL GYLVLHVQAI DADAGDNARL
   541  EYRLAGVGHD FPFTINNGTG WISVAAELDR EEVDFYSFGV EARDHGTPAL TASASVSVTV
   601  LDVNDNNPTF TQPEYTVRLN EDAAVGTSVV TVSAVDRDAH SVITYQITSG NTRNRFSITS
   661  QSGGGLVSLA LPLDYKLERQ YVLAVTASDG TRQDTAQIVV NVTDANTHRP VFQSSHYTVN
   721  VNEDRPAGTT VVLISATDED TGENARITYF MEDSIPQFRI DADTGAVTTQ AELDYEDQVS
   781  YTLAITARDN GIPQKSDTTY LEILVNDVND NAPQFLRDSY QGSVYEDVPP FTSVLQISAT
   841  DRDSGLNGRV FYTFQGGDDG DGDFIVESTS GIVRTLRRLD RENVAQYVLR AYAVDKGMPP
   901  ARTPMEVTVT VLDVNDNPPV FEQDEFDVFV EENSPIGLAV ARVTATDPDE GTNAQIMYQI
   961  VEGNIPEVFQ LDIFSGELTA LVDLDYEDRP EYVLVIQATS APLVSRATVH VRLLDRNDNP
  1021  PVLGNFEILF NNYVTNRSSS FPGGAIGRVP AHDPDISDSL TYSFERGNEL SLVLLNASTG
  1081  ELKLSRALDN NRPLEAIMSV LVSDGVHSVT AQCALRVTII TDEMLTHSIT LRLEDMSPER
  1141  FLSPLLGLFI QAVAATLATP PDHVVVFNVQ RDTDAPGGHI LNVSLSVGQP PGPGGGPPFL
  1201  PSEDLQERLY LNRSLLTAIS AQRVLPFDDN ICLREPCENY MRCVSVLRFD SSAPFIASSS
  1261  VLFRPIHPVG GLRCRCPPGF TGDYCETEVD LCYSRPCGPH GRCRSREGGY TCLCRDGYTG
  1321  EHCEVSARSG RCTPGVCKNG GTCVNLLVGG FKCDCPSGDF EKPYCQVTTR SFPAHSFITF
  1381  RGLRQRFHFT LALSFATKER DGLLLYNGRF NEKHDFVALE VIQEQVQLTF SAGESTTTVS
  1441  PFVPGGVSDG QWHTVQLKYY NKPLLGQTGL PQGPSEQKVA VVTVDGCDTG VALRFGSVLG
  1501  NYSCAAQGTQ GGSKKSLDLT GPLLLGGVPD LPESFPVRMR QFVGCMRNLQ VDSRHIDMAD
  1561  FIANNGTVPG CPAKKNVCDS NTCHNGGTCV NQWDAFSCEC PLGFGGKSCA QEMANPQHFL
  1621  GSSLVAWHGL SLPISQPWYL SLMFRTRQAD GVLLQAITRG RSTITLQLRE GHVMLSVEGT
  1681  GLQASSLRLE PGRANDGDWH HAQLALGASG GPGHAILSFD YGQQRAEGNL GPRLHGLHLS
  1741  NITVGGIPGP AGGVARGFRG CLQGVRVSDT PEGVNSLDPS HGESINVEQG CSLPDPCDSN
  1801  PCPANSYCSN DWDSYSCSCD PGYYGDNCTN VCDLNPCEHQ SVCTRKPSAP HGYTCECPPN
  1861  YLGPYCETRI DQPCPRGWWG HPTCGPCNCD VSKGFDPDCN KTSGECHCKE NHYRPPGSPT
  1921  CLLCDCYPTG SLSRVCDPED GQCPCKPGVI GRQCDRCDNP FAEVTTNGCE VNYDSCPRAI
  1981  EAGIWWPRTR FGLPAAAPCP KGSFGTAVRH CDEHRGWLPP NLFNCTSITF SELKGFAERL
  2041  QRNESGLDSG RSQQLALLLR NATQHTAGYF GSDVKVAYQL ATRLLAHEST QRGFGLSATQ
  2101  DVHFTENLLR VGSALLDTAN KRHWELIQQT EGGTAWLLQH YEAYASALAQ NMRHTYLSPF
  2161  TIVTPNIVIS VVRLDKGNFA GAKLPRYEAL RGEQPPDLET TVILPESVFR ETPPVVRPAG
  2221  PGEAQEPEEL ARRQRRHPEL SQGEAVASVI IYRTLAGLLP HNYDPDKRSL RVPKRPIINT
  2281  PVVSISVHDD EELLPRALDK PVTVQFRLLE TEERTKPICV FWNHSILVSG TGGWSARGCE
  2341  VVFRNESHVS CQCNHMTSFA VLMDVSRREN GEILPLKTLT YVALGVTLAA LLLTFFFLTL
  2401  LRILRSNQHG IRRNLTAALG LAQLVFLLGI NQADLPFACT VIAILLHFLY LCTFSWALLE
  2461  ALHLYRALTE VRDVNTGPMR FYYMLGWGVP AFITGLAVGL DPEGYGNPDF CWLSIYDTLI
  2521  WSFAGPVAFA VSMSVFLYIL AARASCAAQR QGFEKKGPVS GLQPSFAVLL LLSATWLLAL
  2581  LSVNSDTLLF HYLFATCNCI QGPFIFLSYV VLSKEVRKAL KLACSRKPSP DPALTTKSTL
  2641  TSSYNCPSPY ADGRLYQPYG DSAGSLHSTS RSGKSQPSYI PFLLREESAL NPGQGPPGLG
  2701  DPGSLFLEGQ DQQHDPDTDS DSDLSLEDDQ SGSYASTHSS DSEEEEEEEE EEAAFPGEQG
  2761  WDSLLGPGAE RLPLHSTPKD GGPGPGKAPW PGDFGTTAKE SSGNGAPEER LRENGDALSR
  2821  EGSLGPLPGS SAQPHKGILK KKCLPTISEK SSLLRLPLEQ CTGSSRGSSA SEGSRGGPPP
  2881  RPPPRQSLQE QLNGVMPIAM SIKAGTVDED SSGSEFLFFN FLH

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CELSR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0
Highest tissue expression: 24 nTPM

Expression across tissuesHPA

Tissue

cerebral cortex: 24 nTPM
skin: 23 nTPM
hippocampal formation: 17 nTPM
fallopian tube: 15 nTPM
spinal cord: 15 nTPM
esophagus: 12 nTPM

Single-cell type

epididymal principal cells: 72 nCPM
oligodendrocytes: 50 nCPM
fallopian secretory cells: 43 nCPM
müller glia: 37 nCPM
suprabasal keratinocytes: 36 nCPM
ocular epithelial cells: 35 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

hippocampal formation: 199 nTPM
cerebral cortex: 185 nTPM
white matter: 144 nTPM
amygdala: 120 nTPM
basal ganglia: 106 nTPM
medulla oblongata: 91 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about CELSR2.

Disease | GeneticClinVar

2 pathogenic / likely-pathogenic of 805 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.25
gnomAD pLI: 1
gnomAD missense Z: 2.18
DepMap mean gene effect: -0.27
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CELSR2 as an antibody target. Whether an autoantibody or antibody against CELSR2 could matter depends on whether native CELSR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CELSR2 is annotated at the cell surface, where native CELSR2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CELSR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...